Sam-A Pharm. Co. Ltd - Asset Resilience Ratio
Sam-A Pharm. Co. Ltd (009300) has an Asset Resilience Ratio of 36.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Sam-A Pharm. Co. Ltd (009300) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Sam-A Pharm. Co. Ltd's Asset Resilience Ratio has changed over time. See 009300 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sam-A Pharm. Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 009300 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩91.06 Billion | 36.86% |
| Total Liquid Assets | ₩91.06 Billion | 36.86% |
Asset Resilience Insights
- Very High Liquidity: Sam-A Pharm. Co. Ltd maintains exceptional liquid asset reserves at 36.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sam-A Pharm. Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Sam-A Pharm. Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 65.38% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
Annual Asset Resilience Ratio for Sam-A Pharm. Co. Ltd (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Sam-A Pharm. Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.86% | ₩91.06 Billion ≈ $61.71 Million |
₩247.04 Billion ≈ $167.42 Million |
+9.12pp |
| 2024-12-31 | 27.74% | ₩68.99 Billion ≈ $46.76 Million |
₩248.73 Billion ≈ $168.56 Million |
-6.46pp |
| 2023-12-31 | 34.20% | ₩79.10 Billion ≈ $53.61 Million |
₩231.31 Billion ≈ $156.75 Million |
-3.88pp |
| 2022-12-31 | 38.07% | ₩77.37 Billion ≈ $52.43 Million |
₩203.20 Billion ≈ $137.70 Million |
+10.07pp |
| 2021-12-31 | 28.01% | ₩52.98 Billion ≈ $35.90 Million |
₩189.17 Billion ≈ $128.20 Million |
-7.09pp |
| 2020-12-31 | 35.09% | ₩63.91 Billion ≈ $43.31 Million |
₩182.11 Billion ≈ $123.41 Million |
+18.46pp |
| 2019-12-31 | 16.63% | ₩31.73 Billion ≈ $21.50 Million |
₩190.78 Billion ≈ $129.29 Million |
-8.69pp |
| 2018-12-31 | 25.32% | ₩43.99 Billion ≈ $29.81 Million |
₩173.69 Billion ≈ $117.70 Million |
-1.71pp |
| 2017-12-31 | 27.04% | ₩45.41 Billion ≈ $30.77 Million |
₩167.97 Billion ≈ $113.83 Million |
+3.73pp |
| 2016-12-31 | 23.30% | ₩37.81 Billion ≈ $25.63 Million |
₩162.27 Billion ≈ $109.97 Million |
+9.45pp |
| 2015-12-31 | 13.85% | ₩21.18 Billion ≈ $14.35 Million |
₩152.91 Billion ≈ $103.62 Million |
-8.19pp |
| 2014-12-31 | 22.04% | ₩32.15 Billion ≈ $21.79 Million |
₩145.86 Billion ≈ $98.85 Million |
-3.93pp |
| 2012-12-31 | 25.97% | ₩37.61 Billion ≈ $25.49 Million |
₩144.79 Billion ≈ $98.12 Million |
+10.01pp |
| 2011-12-31 | 15.96% | ₩22.00 Billion ≈ $14.91 Million |
₩137.86 Billion ≈ $93.43 Million |
+10.68pp |
| 2010-12-31 | 5.28% | ₩6.79 Billion ≈ $4.60 Million |
₩128.75 Billion ≈ $87.25 Million |
+1.83pp |
| 2009-12-31 | 3.45% | ₩3.83 Billion ≈ $2.60 Million |
₩111.10 Billion ≈ $75.29 Million |
-- |
About Sam-A Pharm. Co. Ltd
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, a… Read more